Praxis Begins Patient Recruitment for Pediatric Epilepsy Research Program
Brentwood, TN
Praxis a company specializing in centralized patient recruitment and retention for clinical research studies, will provide patient recruitment services to a top pharmaceutical company for a study on pediatric epilepsy. This study explores a drug’s effectiveness in very young children. Praxis’ experiences with hard to reach and specialized patient populations is extensive and includes a number of pediatric trials.
Praxis’ successful experiences with hard to reach and specialized patient populations is extensive, and includes a number of pediatric trials. Praxis has helped sponsors successfully enroll pediatric studies:
on average 2 months ahead of schedule
with retention rates most often at 96%, and
with sponsors achieving ROI from ~$1M to ~$3M
“Any time we create and manage a trial involving children there is a real added focus on understanding the mother’s perspective and concerns. We seek to really connect with the mother through images and words that speak to the heart. And by providing content that educates and informs the mom about options, the indication, and the medical research study at hand.” Donna Beasley, VP of operations.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
